The Chairman and CEO of Imagion Biosystems, Bob Proulx, recently spoke with The Market Herald on a significant transaction in the molecular imaging market, and several Company activities, including an update on the HER2 trial initiatives and the new imaging collaboration with Patrys.
The announcement of GE’s acquisition of a small imaging company highlights the value of companies like IBX who are leading the way in molecular imaging. The Company outlined measures to increase patient recruitment for its HER2 clinical trial and discussed the collaboration with Patrys — combining both companies technology to enhance brain cancer imaging.
See the interview here: https://jwp.io/s/d0572UZc
